Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

Published:2018-03-08 Issue: Volume: Page:e1448331
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Kellner Christian¹,Peipp Matthias¹,Gramatzki Martin¹,Schrappe Martin²,Schewe Denis M.²^ORCID

Affiliation:

1. Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany

2. Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University of Kiel, Kiel, Germany, and University Hospital Schleswig-Holstein, Campus Kiel, Germany

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1448331

Reference40 articles.

1. Current progress in innovative engineered antibodies

2. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

3. Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

4. Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies

5. Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody;Frontiers in Immunology;2022-08-31

2. Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis;Blood Advances;2022-08-22

3. Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies;Frontiers in Oncology;2022-06-24

4. Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy;Expert Review of Hematology;2022-03-04

5. An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia;Cancers;2021-04-01